ADVANCED OVARIAN CANCER: OPTIMAL THERAPY UPDATE

VALENCIA, SPAIN.
FEBRUARY 28TH, 2003
PALAU DE LA MÚSICA
AUDITORIUM B

PROGRAM
Advanced Ovarian Cancer: Optimal Therapy. Update

PROGRAM

4th International Symposium

Directors:
JB Vermorken (Antwerp, Belgium)
A Poveda (Valencia, Spain)

Scientific Committee:
MA Bookman (Philadelphia, USA)
A Cervantes (Valencia, Spain)
E Garcia (Valencia, Spain)
C Mendiola (Madrid, Spain)
A Poveda (Valencia, Spain)
JB Trimbos (Leiden, The Netherlands)
JB Vermorken (Antwerp, Belgium)
08.30h
WELCOME

09.00-11.00h
1st SESSION
Chairmen: Lorem Ipsum Dolor

- Proteomic analysis for early detection of ovarian cancer: a realistic approach
  - Juma C. Akin (NCI, Bethesda)

- Update of conventional screening methods for ovarian cancer
  - Ian J Jacobs (London, United Kingdom)

- What have we learned from ICON-1 and ACTION?
  - Sergio Pecorelli (Brescia, Italy)
  - Nicoletta Colombo (Milan, Italy)

11.00h
COFFE BREAK

11.30-13.30h
2nd SESSION
Chairmen: Lorem Ipsum Dolor

- Gold standard for first-line chemotherapy in advanced ovarian cancer
  * Long-term follow-up of GOG-111 and OV10
    - Martine Piccart (Brussels, Belgium)

- Carboplatin/paclitaxel vs cisplatin/paclitaxel
  - Michael A Bookman (Philadelphia, USA)

- Sequential single agent chemotherapy vs combination chemotherapy
  - Franco M Muggia (New York, USA)

- The potential role of neoadjuvant chemotherapy in advanced ovarian cancer
  - Mark Baekelandt (Oslo, Norway)

11.00h
LUNCH
15.00-17.30h
3rd SESSION

Chairmen: Lorem Ipsum Dolor

- The role of anthracyclines in ovarian cancer
  - Update of AGO GINECO study
    Andreas du Bois (Frankfurt, Germany)
  - Update of NSGO/ORTC/GEICO/NCIC study
    Gunnar Kristensen (Oslo, Norway)
  - The role of anthracyclines in second-line treatment
    Jan Baptiste Vermorken (Antwerp, Belgium)

- Is combination chemotherapy superior over single-agent chemotherapy in second-line treatment?
  - Miguel A Izquierdo (Barcelona, Spain)

- Consolidation therapies revisited
  - Radiotherapy
    - Börje (Örebro, Sweden)
  - IP chemotherapy
    - Martine Piccart (Brussels, Belgium)

17.30h
TEA

17.45-19.15h
4th SESSION

Chairmen: Lorem Ipsum Dolor

- Cost-effectiveness studies in ovarian cancer
  - Thomas D Szucs (Switzerland)

- Translation research in ovarian cancer: a must
  - Thomas C Hamilton (Philadelphia, USA)

- Treatment policies for the next 10 years
  - Elisabeth Eisenhauer (Kingston, Canada)

- Remarks and Conclusion
  - Andres Poveda (Valencia, Spain)
VENUE
All sessions will take place at PALAU DE LA MUSICA.
Paseo Alameda, 30. 46023 VALENCIA. Spain

SCIENTIFIC SECRETARIAT
Dr. ANDRÉS POVEDA.
Fundación IVO.
C/ Professor Baguena, 8. 46009 VALENCIA. Spain
Phone: (34) 96 111 41 28
Fax: (34) 96 111 43 44
E-mail: apoveda@ene.es
apoveda@fivo.org

ORGANIZING SECRETARIAT
(Registration and Accommodation):
ULTRAMAR EXPRESS, Congressos.
Gran Vía Marqués de Turia, 48 715, 46005 VALENCIA. SPAIN.
Phone (34) 96 252 81 61
E-mail: bcalatrava@uex.es

CREDITS
The symposium has been accredited by the European Society of Medical Oncology Educational Committee for its medical oncology recertification approval (ESMO/MORA) program with 7 credit points category 1.

LANGUAGE
The official language of the Symposium is English.
Simultaneous translation into Spanish will be provided.